|
A pair of
studies appears to have confirmed the importance of C-reactive
protein in coronary heart disease. The studies were designed
to compare aggressive statin
therapy versus moderate statin therapy while measuring the
relationship between LDL cholesterol and C- reactive protein in coronary artery disease.
Previous studies have confirmed that statins, which inhibit
cholesterol synthesis in the blood, can reduce the level of
LDL cholesterol and C-reactive protein, but the relationship
between the two, and between C-reactive protein and
atherosclerosis, was always uncertain. The pair
of studies found that aggressive statin therapy lowered the
levels of both LDL cholesterol and C-reactive protein,
compared to moderate statin therapy. Furthermore, people with
lower levels of both experienced fewer heart attacks or
cardiovascular events. Perhaps more importantly, the studies
also found that patients with lower levels of C-reactive
protein fared better than patients with higher levels of
C-reactive protein, regardless of their cholesterol level.
According to the researchers, this strongly suggests an
independent role for inflammation in atherosclerosis. Based on
this, the authors of the study recommend that C- reactive
protein, as well as cholesterol levels, should be monitored
during statin therapy. Moreover, patients on moderate doses on
statins might consider increasing their dosage to reduce their
risk of heart attack. |